Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial of pacritinib in myelofibrosis patients with severe thrombocytopenia

Trial Profile

Phase 3 trial of pacritinib in myelofibrosis patients with severe thrombocytopenia

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Myelofibrosis; Thrombocytopenia
  • Focus Registrational; Therapeutic Use
  • Acronyms PACIFICA
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 18 Jul 2019 According to a CTI BioPharma media release, Professor Claire Harrison, Professor of Medicine, Guy's and St Thomas' NHS Foundation Trust, London, will chair the study's Steering Committee.
    • 18 Jul 2019 According to a CTI BioPharma media release, Dr. Srdam Verstovsek, Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and Dr. John Mascarenhas, Associate Professor of Medicine Myeloproliferative Disorders Program, Tisch Cancer Institute, Mount Sinai School of Medicine, will be co-principal investigators in the study.
    • 18 Jul 2019 According to a CTI BioPharma media release, the company expects to report topline data from the study in mid-2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top